GALAPAGOS NV-SPON ADR (GLPG) Stock Price & Overview
NASDAQ:GLPG • US36315X1019
The current stock price of GLPG is 33.38 USD. Today GLPG is down by -0.92%. In the past month the price decreased by -3.61%. In the past year, price increased by 25.58%.
GLPG Key Statistics
- Market Cap
- 2.2B
- P/E
- 5.89
- Fwd P/E
- N/A
- EPS (TTM)
- 5.67
- Dividend Yield
- N/A
GLPG Stock Performance
GLPG Stock Chart
GLPG Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to GLPG. When comparing the yearly performance of all stocks, GLPG is one of the better performing stocks in the market, outperforming 76.32% of all stocks.
GLPG Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to GLPG. GLPG has only an average score on both its financial health and profitability.
GLPG Earnings
On February 24, 2026 GLPG reported an EPS of 11.87 and a revenue of 900.77M. The company beat EPS expectations (329.89% surprise) and beat revenue expectations (977.92% surprise).
GLPG Forecast & Estimates
18 analysts have analysed GLPG and the average price target is 37.13 USD. This implies a price increase of 11.24% is expected in the next year compared to the current price of 33.38.
For the next year, analysts expect an EPS growth of -150.44% and a revenue growth -0.05% for GLPG
GLPG Groups
Sector & Classification
GLPG Financial Highlights
Over the last trailing twelve months GLPG reported a non-GAAP Earnings per Share(EPS) of 5.67. The EPS increased by 334.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.85% | ||
| ROA | 9.42% | ||
| ROE | 9.92% | ||
| Debt/Equity | 0 |
GLPG Ownership
GLPG Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16 | 417.437B | ||
| AMGN | AMGEN INC | 16.31 | 204.229B | ||
| GILD | GILEAD SCIENCES INC | 16.27 | 183.894B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.6 | 121.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 83.255B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.84 | 43.24B | ||
| INSM | INSMED INC | N/A | 31.965B | ||
| NTRA | NATERA INC | N/A | 28.775B | ||
| BIIB | BIOGEN INC | 12.36 | 27.876B | ||
| MRNA | MODERNA INC | N/A | 22.581B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.24 | 21.486B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.053B | ||
| EXAS | EXACT SCIENCES CORP | 308.82 | 19.749B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GLPG
Company Profile
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 704 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Company Info
GALAPAGOS NV-SPON ADR
Generaal De Wittelaan L11 A3
MALINES (MECHELEN) ANTWERPEN 2800 BE
CEO: Onnovan deStolpe
Employees: 704
Phone: 3215342900
GALAPAGOS NV-SPON ADR / GLPG FAQ
What does GLPG do?
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 704 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Can you provide the latest stock price for GALAPAGOS NV-SPON ADR?
The current stock price of GLPG is 33.38 USD. The price decreased by -0.92% in the last trading session.
Does GLPG stock pay dividends?
GLPG does not pay a dividend.
What is the ChartMill rating of GALAPAGOS NV-SPON ADR stock?
GLPG has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists GLPG stock?
GLPG stock is listed on the Nasdaq exchange.
How is the valuation of GALAPAGOS NV-SPON ADR (GLPG) based on its PE ratio?
The PE ratio for GALAPAGOS NV-SPON ADR (GLPG) is 5.89. This is based on the reported non-GAAP earnings per share of 5.67 and the current share price of 33.38 USD.
Can you provide the short interest for GLPG stock?
The outstanding short interest for GALAPAGOS NV-SPON ADR (GLPG) is 1.53% of its float.